Alkermes plc (ALKS) 10-Year Financial Performance & Capital Metrics

ALKS • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersPsychiatric & CNS Disorders

AboutAlkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.Show more

Revenue $1.56B -6.4%
EBITDA $449M -8.2%
Net Income $367M +3.2%
EPS (Diluted) 2.17 +3.3%
Gross Margin 84.25% -0.6%
EBITDA Margin 28.84% -1.9%
Operating Margin 27% +8.5%
Net Margin 23.57% +10.2%
ROE 27.52% -13.1%
ROIC 26.66% -3.5%
Debt/Equity 0.05 -83.3%
Interest Coverage 18.63 +3.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Strong Piotroski F-Score: 7/9
✓FCF machine: 26.0% free cash flow margin

✗Weaknesses

No significant weaknesses identified

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y9.67%

5Y5.87%

3Y9.89%

TTM1.08%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM1.64%

EPS CAGR

10Y-

5Y-

3Y-

TTM3.59%

ROCE

10Y Avg-0.36%

5Y Avg10.28%

3Y Avg17.57%

Latest26.24%

Peer Comparison

Psychiatric & CNS Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
ACADACADIA Pharmaceuticals Inc.	4.54B	26.86	19.75	31.85%	24.94%	28.47%	3.46%	0.07
JAZZJazz Pharmaceuticals plc	10.38B	170.81	19.75	6.12%	-8.86%	-9.31%	12.99%	1.51
CPRXCatalyst Pharmaceuticals, Inc.	2.85B	23.17	17.69	23.49%	37.63%	23.64%	8.4%	0.00
HRMYHarmony Biosciences Holdings, Inc.	2.08B	36.04	14.36	22.8%	22.48%	22.23%	10.53%	0.28
ALKSAlkermes plc	5.06B	30.62	14.11	-6.36%	22.27%	19.55%	8.02%	0.05
PRTCPureTech Health plc	458.47M	18.97	9.49	44.98%	-495.91%	-8.53%		0.05
LBRXLB Pharmaceuticals Inc Common Stock	489.79M	19.36	-1.09
NMRANeumora Therapeutics, Inc. Common Stock	365.37M	2.15	-1.41			-178.79%		0.01

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	628.34M	745.69M	903.37M	1.09B	1.17B	1.04B	1.17B	1.11B	1.66B	1.56B
Revenue Growth %	0.02%	0.19%	0.21%	0.21%	0.07%	-0.11%	0.13%	-0.05%	0.5%	-0.06%
Cost of Goods Sold+	138.99M	132.12M	154.75M	176.42M	180.38M	178.32M	197.32M	218.07M	253.04M	245.33M
COGS % of Revenue	0.22%	0.18%	0.17%	0.16%	0.15%	0.17%	0.17%	0.2%	0.15%	0.16%
Gross Profit+	489.35M	613.57M	748.63M	917.85M	990.56M	860.44M	976.43M	893.73M	1.41B	1.31B
Gross Margin %	0.78%	0.82%	0.83%	0.84%	0.85%	0.83%	0.83%	0.8%	0.85%	0.84%
Gross Profit Growth %	0.1%	0.25%	0.22%	0.23%	0.08%	-0.13%	0.13%	-0.08%	0.58%	-0.07%
Operating Expenses+	713.65M	822.24M	896.53M	1.02B	1.17B	972.87M	878.68M	899.82M	996.25M	891.66M
OpEx % of Revenue	1.14%	1.1%	0.99%	0.93%	1%	0.94%	0.75%	0.81%	0.6%	0.57%
Selling, General & Admin	311.56M	374.13M	421.58M	526.41M	599.45M	538.83M	549.61M	590.75M	689.75M	645.24M
SG&A % of Revenue	0.5%	0.5%	0.47%	0.48%	0.51%	0.52%	0.47%	0.53%	0.41%	0.41%
Research & Development	344.4M	387.15M	412.89M	425.41M	512.83M	394.59M	290.92M	272.7M	270.81M	245.33M
R&D % of Revenue	0.55%	0.52%	0.46%	0.39%	0.44%	0.38%	0.25%	0.25%	0.16%	0.16%
Other Operating Expenses	57.69M	60.96M	62.06M	65.17M	53.76M	39.45M	38.15M	36.36M	35.69M	1.1M
Operating Income+	-224.3M	-208.66M	-147.9M	-99.13M	-175.48M	-112.43M	97.75M	-6.09M	414.12M	420.64M
Operating Margin %	-0.36%	-0.28%	-0.16%	-0.09%	-0.15%	-0.11%	0.08%	-0.01%	0.25%	0.27%
Operating Income Growth %	-1.57%	0.07%	0.29%	0.33%	-0.77%	0.36%	1.87%	-1.06%	69.01%	0.02%
EBITDA+	-138.71M	-114.41M	-49.38M	4.53M	-95.07M	-30.57M	176.4M	71.77M	489.05M	449.17M
EBITDA Margin %	-0.22%	-0.15%	-0.05%	0%	-0.08%	-0.03%	0.15%	0.06%	0.29%	0.29%
EBITDA Growth %	-13.68%	0.18%	0.57%	1.09%	-21.98%	0.68%	6.77%	-0.59%	5.81%	-0.08%
D&A (Non-Cash Add-back)	85.6M	94.26M	98.52M	103.66M	80.41M	81.85M	78.65M	77.86M	74.93M	28.53M
EBIT	-210.76M	-199.5M	-131.27M	-111.53M	-183.46M	-87.88M	98.95M	-18.09M	444.55M	466.33M
Net Interest Income+	-9.92M	-11.14M	-7.36M	-6.2M	375K	-1.7M	-8.81M	-5.41M	7.82M	19.87M
Interest Income	3.33M	3.75M	4.65M	9.24M	13.98M	6.96M	2.41M	7.63M	30.85M	42.45M
Interest Expense	13.25M	14.89M	12.01M	15.44M	13.6M	8.66M	11.22M	13.04M	23.03M	22.58M
Other Income/Expense	296K	-5.72M	4.63M	-27.84M	-21.58M	15.89M	-10.02M	-25.04M	7.4M	23.11M
Pretax Income+	-224M	-214.39M	-143.27M	-126.97M	-197.06M	-96.54M	87.73M	-31.13M	421.52M	443.75M
Pretax Margin %	-0.36%	-0.29%	-0.16%	-0.12%	-0.17%	-0.09%	0.07%	-0.03%	0.25%	0.28%
Income Tax+	3.16M	-5.94M	14.67M	12.34M	-436K	14.32M	11.33M	2.02M	-97.64M	71.61M
Effective Tax Rate %	1.01%	0.97%	1.1%	1.1%	1%	1.15%	-0.55%	5.08%	0.84%	0.83%
Net Income+	-227.16M	-208.44M	-157.94M	-139.31M	-196.62M	-110.86M	-48.17M	-158.27M	355.76M	367.07M
Net Margin %	-0.36%	-0.28%	-0.17%	-0.13%	-0.17%	-0.11%	-0.04%	-0.14%	0.21%	0.24%
Net Income Growth %	-6.56%	0.08%	0.24%	0.12%	-0.41%	0.44%	0.57%	-2.29%	3.25%	0.03%
Net Income (Continuing)	-227.16M	-208.44M	-157.94M	-139.31M	-196.62M	-110.86M	76.4M	-33.15M	519.16M	372.14M
Discontinued Operations	0	0	0	0	0	0	-124.57M	-125.11M	-163.4M	-5.07M
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1.52	-1.38	-1.03	-0.90	-1.25	-0.70	-0.30	-0.97	2.10	2.17
EPS Growth %	-6.24%	0.09%	0.25%	0.13%	-0.39%	0.44%	0.57%	-2.23%	3.16%	0.03%
EPS (Basic)	-1.52	-1.38	-1.03	-0.90	-1.25	-0.70	-0.30	-0.97	2.14	2.22
Diluted Shares Outstanding	149.21M	151.48M	153.41M	155.11M	157.05M	158.8M	160.94M	163.74M	169.73M	169.2M
Basic Shares Outstanding	149.21M	151.48M	153.41M	155.11M	157.05M	158.8M	160.94M	163.74M	166.22M	165.39M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	1.02B	912.61M	966.06M	983.25M	961.97M	1.11B	1.06B	1.13B	1.49B	1.42B
Cash & Short-Term Investments	798.85M	619.16M	590.72M	539.29M	534.98M	635.03M	536.31M	608.47M	773.49M	751.67M
Cash Only	181.11M	186.38M	191.3M	266.76M	203.77M	272.96M	337.54M	292.47M	457.47M	291.15M
Short-Term Investments	353.67M	310.86M	242.21M	272.53M	331.21M	362.07M	198.77M	315.99M	316.02M	460.52M
Accounts Receivable	155.49M	191.1M	233.59M	300.45M	265.47M	289.54M	326.56M	296.9M	333.18M	389.52M
Days Sales Outstanding	90.32	93.54	94.38	100.22	82.75	101.74	101.55	97.47	73.11	91.28
Inventory	38.41M	63M	93.28M	90.2M	101.8M	125.74M	150.34M	181.42M	186.41M	182.89M
Days Inventory Outstanding	100.87	174.04	220.01	186.61	205.99	257.38	278.08	303.66	268.89	272.1
Other Current Assets	0	0	0	0	0	0	0	43.53M	192.43M	91.28M
Total Non-Current Assets+	836.71M	813.81M	831.17M	841.75M	843.43M	838.76M	962.32M	833.67M	650.72M	640.21M
Property, Plant & Equipment	254.82M	264.79M	284.74M	309.99M	374.55M	481.72M	456.68M	320.46M	318.4M	311.81M
Fixed Asset Turnover	2.47x	2.82x	3.17x	3.53x	3.13x	2.16x	2.57x	3.47x	5.22x	5.00x
Goodwill	92.87M	92.87M	92.87M	92.87M	92.87M	92.87M	92.87M	83.03M	83.03M	83.03M
Intangible Assets	379.19M	318.23M	256.17M	191M	150.64M	111.19M	74.04M	37.68M	1.99M	890K
Long-Term Investments	264.07M	121.93M	157.21M	80.74M	79.39M	24.78M	229.43M	131.61M	39.89M	73.15M
Other Non-Current Assets	-195.09M	-31.77M	-58.38M	81.34M	49.42M	41.97M	27.45M	146.32M	11.52M	16.5M
Total Assets+	1.86B	1.73B	1.8B	1.83B	1.81B	1.95B	2.02B	1.96B	2.14B	2.06B
Asset Turnover	0.34x	0.43x	0.50x	0.60x	0.65x	0.53x	0.58x	0.57x	0.78x	0.76x
Asset Growth %	-0.03%	-0.07%	0.04%	0.02%	-0.01%	0.08%	0.04%	-0.03%	0.09%	-0.04%
Total Current Liabilities+	236.21M	211.99M	291.12M	339.77M	391.11M	438.26M	471.29M	497.74M	520.22M	465.2M
Accounts Payable	37.4M	46.27M	55.53M	39.77M	54.26M	46.03M	55.72M	32.84M	65.65M	45.63M
Days Payables Outstanding	98.22	127.84	130.97	82.28	109.79	94.23	103.07	54.97	94.7	67.89
Short-Term Debt	65.74M	3M	3M	2.84M	2.84M	2.84M	3M	3M	3M	0
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	90.96M	114.26M	176.07M	226.38M	72.07M	71.18M	77.26M	84.93M	359.99M	70.96M
Current Ratio	4.31x	4.30x	3.32x	2.89x	2.46x	2.53x	2.25x	2.27x	2.86x	3.04x
Quick Ratio	4.15x	4.01x	3.00x	2.63x	2.20x	2.25x	1.93x	1.91x	2.50x	2.65x
Cash Conversion Cycle	92.97	139.74	183.42	204.55	178.95	264.89	276.56	346.15	247.3	295.48
Total Non-Current Liabilities+	305.26M	304.95M	303.3M	313.95M	328.85M	444.49M	440.61M	422.48M	413.32M	125.39M
Long-Term Debt	284.21M	280.67M	278.44M	276.46M	274.3M	272.12M	292.8M	290.27M	287.73M	0
Capital Lease Obligations	0	0	0	0	5.34M	119.46M	104.16M	76.29M	75.71M	69.37M
Deferred Tax Liabilities	470K	0	0	0	0	0	0	0	-4.78M	0
Other Non-Current Liabilities	12.61M	17.16M	19.2M	27.96M	27.14M	36.51M	32.16M	55.93M	49.88M	56.02M
Total Liabilities	541.47M	516.94M	594.42M	653.72M	719.96M	882.75M	911.9M	920.23M	933.54M	590.59M
Total Debt+	349.94M	283.67M	281.44M	279.31M	290.95M	410.16M	416.21M	379.44M	372.19M	75.54M
Net Debt	168.84M	97.29M	90.14M	12.55M	87.17M	137.2M	78.66M	86.96M	-85.28M	-215.61M
Debt / Equity	0.27x	0.23x	0.23x	0.24x	0.27x	0.38x	0.37x	0.36x	0.31x	0.05x
Debt / EBITDA	-	-	-	61.63x	-	-	2.36x	5.29x	0.76x	0.17x
Net Debt / EBITDA	-	-	-	2.77x	-	-	0.45x	1.21x	-0.17x	-0.48x
Interest Coverage	-16.93x	-14.01x	-12.32x	-6.42x	-12.90x	-12.98x	8.71x	-0.47x	17.98x	18.63x
Total Equity+	1.31B	1.21B	1.2B	1.17B	1.09B	1.07B	1.11B	1.04B	1.2B	1.46B
Equity Growth %	-0.06%	-0.08%	-0.01%	-0.03%	-0.07%	-0.02%	0.04%	-0.06%	0.15%	0.22%
Book Value per Share	8.81	7.98	7.84	7.55	6.91	6.72	6.91	6.37	7.09	8.66
Total Shareholders' Equity	1.31B	1.21B	1.2B	1.17B	1.09B	1.07B	1.11B	1.04B	1.2B	1.46B
Common Stock	1.52M	1.54M	1.56M	1.58M	1.6M	1.62M	1.66M	1.69M	1.73M	1.77M
Retained Earnings	-739.5M	-947.94M	-1.04B	-1.19B	-1.38B	-1.49B	-1.54B	-1.7B	-1.34B	-976.46M
Treasury Stock	-58.66M	-72.64M	-89.35M	-108.97M	-118.39M	-126.09M	-142.66M	-160.86M	-189.34M	-419.25M
Accumulated OCI	-3.79M	-3.27M	-3.79M	-3.28M	-1.82M	-1.35M	-3.72M	-10.89M	-3.11M	-1.97M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-40.36M	-63.8M	19.19M	99.28M	72.08M	82.84M	101.72M	21.04M	401.35M	439.12M
Operating CF Margin %	-0.06%	-0.09%	0.02%	0.09%	0.06%	0.08%	0.09%	0.02%	0.24%	0.28%
Operating CF Growth %	-4.62%	-0.58%	1.3%	4.17%	-0.27%	0.15%	0.23%	-0.79%	18.07%	0.09%
Net Income	-227.16M	-208.44M	-157.94M	-139.31M	-196.62M	-110.86M	-48.17M	-158.27M	355.76M	367.07M
Depreciation & Amortization	85.6M	94.26M	98.52M	103.66M	80.41M	81.85M	78.65M	77.86M	74.93M	28.53M
Stock-Based Compensation	97.34M	94.4M	83.92M	105.36M	0	90.16M	87.62M	94.25M	100.91M	96.64M
Deferred Taxes	-37.58M	-9.69M	7.23M	10.62M	-319K	9.98M	5.08M	-32.8M	-99.9M	40.52M
Other Non-Cash Items	-40.53M	-7.12M	-7.66M	26.37M	123.2M	-1.43M	4.08M	27.28M	6.33M	4.51M
Working Capital Changes	81.98M	-27.2M	-4.88M	-7.42M	65.41M	13.13M	-25.55M	12.71M	-36.66M	-98.15M
Change in Receivables	-16.45M	-35.62M	-42.49M	-58.63M	29.98M	-18.05M	-38.01M	25.25M	-44.51M	-56.34M
Change in Inventory	19.62M	-26.38M	-30.19M	-2.67M	-13.08M	-22.93M	-24.77M	-31.02M	-2.71M	3.09M
Change in Payables	76.16M	45.87M	72.66M	46.74M	34.85M	59.04M	43.31M	15.53M	23.01M	-57.97M
Cash from Investing+	-43.49M	127.24M	-18.36M	-22.2M	-141.83M	-11.48M	-66.2M	-64.54M	53.36M	-111.31M
Capital Expenditures	-52.88M	-43.66M	-51.3M	-69.43M	-90.94M	-42.22M	-29.02M	-38.26M	-48.05M	-33.48M
CapEx % of Revenue	0.08%	0.06%	0.06%	0.06%	0.08%	0.04%	0.02%	0.03%	0.03%	0.02%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	50.5M	194K	162K	507K	10M	4.53M	8.94M	1.27M	354K	461K
Cash from Financing+	40.89M	-58.17M	4.08M	-1.62M	6.76M	-2.17M	29.07M	-1.57M	-289.71M	-494.14M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	47.64M	7.64M	4.08M	-877K	0	0	0	0	-275M	-2.06M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-93.24M	-107.46M	-32.11M	29.85M	-18.86M	40.62M	72.69M	-17.21M	353.31M	405.64M
FCF Margin %	-0.15%	-0.14%	-0.04%	0.03%	-0.02%	0.04%	0.06%	-0.02%	0.21%	0.26%
FCF Growth %	-3.14%	-0.15%	0.7%	1.93%	-1.63%	3.15%	0.79%	-1.24%	21.53%	0.15%
FCF per Share	-0.62	-0.71	-0.21	0.19	-0.12	0.26	0.45	-0.11	2.08	2.40
FCF Conversion (FCF/Net Income)	0.18x	0.31x	-0.12x	-0.71x	-0.37x	-0.75x	-2.11x	-0.13x	1.13x	1.20x
Interest Paid	12.32M	12.46M	11.14M	12.53M	0	8.29M	6.9M	13.56M	22.75M	23.01M
Taxes Paid	705K	5.53M	2.99M	754K	0	620K	1.89M	20.75M	44.24M	2.59M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-16.76%	-16.52%	-13.1%	-11.74%	-17.43%	-10.3%	-4.42%	-14.68%	31.67%	27.52%
Return on Invested Capital (ROIC)	-11.16%	-11.22%	-8.53%	-6%	-11.17%	-7.1%	6.12%	-0.39%	27.63%	26.66%
Gross Margin	77.88%	82.28%	82.87%	83.88%	84.59%	82.83%	83.19%	80.39%	84.79%	84.25%
Net Margin	-36.15%	-27.95%	-17.48%	-12.73%	-16.79%	-10.67%	-4.1%	-14.24%	21.39%	23.57%
Debt / Equity	0.27x	0.23x	0.23x	0.24x	0.27x	0.38x	0.37x	0.36x	0.31x	0.05x
Interest Coverage	-16.93x	-14.01x	-12.32x	-6.42x	-12.90x	-12.98x	8.71x	-0.47x	17.98x	18.63x
FCF Conversion	0.18x	0.31x	-0.12x	-0.71x	-0.37x	-0.75x	-2.11x	-0.13x	1.13x	1.20x
Revenue Growth	1.54%	18.68%	21.15%	21.13%	7.01%	-11.29%	13%	-5.28%	49.61%	-6.36%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Product	-	-	-	-	524.5M	-	627.42M	777.55M	920M	1.08B
Product Growth	-	-	-	-	-	-	-	23.93%	18.32%	17.78%
Vivitrol	-	-	-	302.61M	335.37M	-	343.85M	379.48M	400.42M	457.31M
Vivitrol Growth	-	-	-	-	10.82%	-	-	10.36%	5.52%	14.21%
Aristada And Aristada Initio	-	-	-	-	-	-	275.36M	302.05M	327.69M	346.19M
Aristada And Aristada Initio Growth	-	-	-	-	-	-	-	9.70%	8.49%	5.64%
L Y B A L V I	-	-	-	-	-	-	8.21M	96.02M	191.89M	280.03M
L Y B A L V I Growth	-	-	-	-	-	-	-	1068.86%	99.84%	45.93%
Manufactured Product And Royalty	-	-	-	-	-	22.5M	-	-	-	-
Manufactured Product And Royalty Growth	-	-	-	-	-	-	-	-	-	-
Research And Development	-	-	-	-	-	1.95M	-	-	-	-
Research And Development Growth	-	-	-	-	-	-	-	-	-	-
License	-	-	-	-	-	1.05M	-	-	-	-
License Growth	-	-	-	-	-	-	-	-	-	-
Aristada Or Aristada Initio	-	-	-	-	189.13M	-	-	-	-	-
Aristada Or Aristada Initio Growth	-	-	-	-	-	-	-	-	-	-
Aristada	-	-	-	147.72M	-	-	-	-	-	-
Aristada Growth	-	-	-	-	-	-	-	-	-	-
B Y D U R E O N	-	-	45.7M	-	-	-	-	-	-	-
B Y D U R E O N Growth	-	-	-	-	-	-	-	-	-	-
R I S P E R D A L C O N S T A	24.2M	22.3M	20.1M	-	-	-	-	-	-	-
R I S P E R D A L C O N S T A Growth	-	-7.85%	-9.87%	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
UNITED STATES	-	-	-	884.6M	966.93M	839M	984.24M	931.99M	1.49B	1.41B
UNITED STATES Growth	-	-	-	-	9.31%	-13.23%	17.31%	-5.31%	60.08%	-5.48%
Foreign Country Excluding Specified Country	175.79M	183.97M	193.58M	204.76M	200.82M	196.53M	187.34M	177.97M	170.29M	146.18M
Foreign Country Excluding Specified Country Growth	-	4.65%	5.22%	5.78%	-1.92%	-2.14%	-4.67%	-5.00%	-4.32%	-14.16%
IRELAND	-	-	-	4.92M	3.19M	3.23M	2.17M	1.83M	1.18M	1.29M
IRELAND Growth	-	-	-	-	-34.99%	1.19%	-32.73%	-15.91%	-35.54%	9.75%
U	448.64M	557.31M	700.09M	-	-	-	-	-	-	-
U Growth	-	24.22%	25.62%	-	-	-	-	-	-	-
I	3.9M	4.41M	9.71M	-	-	-	-	-	-	-
I Growth	-	12.94%	120.24%	-	-	-	-	-	-	-

Frequently Asked Questions

Valuation & Price

Alkermes plc (ALKS) has a price-to-earnings (P/E) ratio of 14.1x. This may indicate the stock is undervalued or faces growth challenges.

Growth & Financials

Alkermes plc (ALKS) reported $1.52B in revenue for fiscal year 2024. This represents a 290% increase from $390.0M in 2011.

Alkermes plc (ALKS) saw revenue decline by 6.4% over the past year.

Yes, Alkermes plc (ALKS) is profitable, generating $338.8M in net income for fiscal year 2024 (23.6% net margin).

Dividend & Returns

Alkermes plc (ALKS) has a return on equity (ROE) of 27.5%. This is excellent, indicating efficient use of shareholder capital.

Alkermes plc (ALKS) generated $490.9M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...

Alkermes plc (ALKS) 10-Year Financial Performance & Capital Metrics

ALKS • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersPsychiatric & CNS Disorders

Revenue $1.56B -6.4%
EBITDA $449M -8.2%
Net Income $367M +3.2%
EPS (Diluted) 2.17 +3.3%
Gross Margin 84.25% -0.6%
EBITDA Margin 28.84% -1.9%
Operating Margin 27% +8.5%
Net Margin 23.57% +10.2%
ROE 27.52% -13.1%
ROIC 26.66% -3.5%
Debt/Equity 0.05 -83.3%
Interest Coverage 18.63 +3.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Strong Piotroski F-Score: 7/9
✓FCF machine: 26.0% free cash flow margin

✗Weaknesses

No significant weaknesses identified

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y9.67%

5Y5.87%

3Y9.89%

TTM1.08%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM1.64%

EPS CAGR

10Y-

5Y-

3Y-

TTM3.59%

ROCE

10Y Avg-0.36%

5Y Avg10.28%

3Y Avg17.57%

Latest26.24%

Peer Comparison

Psychiatric & CNS Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
ACADACADIA Pharmaceuticals Inc.	4.54B	26.86	19.75	31.85%	24.94%	28.47%	3.46%	0.07
JAZZJazz Pharmaceuticals plc	10.38B	170.81	19.75	6.12%	-8.86%	-9.31%	12.99%	1.51
CPRXCatalyst Pharmaceuticals, Inc.	2.85B	23.17	17.69	23.49%	37.63%	23.64%	8.4%	0.00
HRMYHarmony Biosciences Holdings, Inc.	2.08B	36.04	14.36	22.8%	22.48%	22.23%	10.53%	0.28
ALKSAlkermes plc	5.06B	30.62	14.11	-6.36%	22.27%	19.55%	8.02%	0.05
PRTCPureTech Health plc	458.47M	18.97	9.49	44.98%	-495.91%	-8.53%		0.05
LBRXLB Pharmaceuticals Inc Common Stock	489.79M	19.36	-1.09
NMRANeumora Therapeutics, Inc. Common Stock	365.37M	2.15	-1.41			-178.79%		0.01

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	628.34M	745.69M	903.37M	1.09B	1.17B	1.04B	1.17B	1.11B	1.66B	1.56B
Revenue Growth %	0.02%	0.19%	0.21%	0.21%	0.07%	-0.11%	0.13%	-0.05%	0.5%	-0.06%
Cost of Goods Sold+	138.99M	132.12M	154.75M	176.42M	180.38M	178.32M	197.32M	218.07M	253.04M	245.33M
COGS % of Revenue	0.22%	0.18%	0.17%	0.16%	0.15%	0.17%	0.17%	0.2%	0.15%	0.16%
Gross Profit+	489.35M	613.57M	748.63M	917.85M	990.56M	860.44M	976.43M	893.73M	1.41B	1.31B
Gross Margin %	0.78%	0.82%	0.83%	0.84%	0.85%	0.83%	0.83%	0.8%	0.85%	0.84%
Gross Profit Growth %	0.1%	0.25%	0.22%	0.23%	0.08%	-0.13%	0.13%	-0.08%	0.58%	-0.07%
Operating Expenses+	713.65M	822.24M	896.53M	1.02B	1.17B	972.87M	878.68M	899.82M	996.25M	891.66M
OpEx % of Revenue	1.14%	1.1%	0.99%	0.93%	1%	0.94%	0.75%	0.81%	0.6%	0.57%
Selling, General & Admin	311.56M	374.13M	421.58M	526.41M	599.45M	538.83M	549.61M	590.75M	689.75M	645.24M
SG&A % of Revenue	0.5%	0.5%	0.47%	0.48%	0.51%	0.52%	0.47%	0.53%	0.41%	0.41%
Research & Development	344.4M	387.15M	412.89M	425.41M	512.83M	394.59M	290.92M	272.7M	270.81M	245.33M
R&D % of Revenue	0.55%	0.52%	0.46%	0.39%	0.44%	0.38%	0.25%	0.25%	0.16%	0.16%
Other Operating Expenses	57.69M	60.96M	62.06M	65.17M	53.76M	39.45M	38.15M	36.36M	35.69M	1.1M
Operating Income+	-224.3M	-208.66M	-147.9M	-99.13M	-175.48M	-112.43M	97.75M	-6.09M	414.12M	420.64M
Operating Margin %	-0.36%	-0.28%	-0.16%	-0.09%	-0.15%	-0.11%	0.08%	-0.01%	0.25%	0.27%
Operating Income Growth %	-1.57%	0.07%	0.29%	0.33%	-0.77%	0.36%	1.87%	-1.06%	69.01%	0.02%
EBITDA+	-138.71M	-114.41M	-49.38M	4.53M	-95.07M	-30.57M	176.4M	71.77M	489.05M	449.17M
EBITDA Margin %	-0.22%	-0.15%	-0.05%	0%	-0.08%	-0.03%	0.15%	0.06%	0.29%	0.29%
EBITDA Growth %	-13.68%	0.18%	0.57%	1.09%	-21.98%	0.68%	6.77%	-0.59%	5.81%	-0.08%
D&A (Non-Cash Add-back)	85.6M	94.26M	98.52M	103.66M	80.41M	81.85M	78.65M	77.86M	74.93M	28.53M
EBIT	-210.76M	-199.5M	-131.27M	-111.53M	-183.46M	-87.88M	98.95M	-18.09M	444.55M	466.33M
Net Interest Income+	-9.92M	-11.14M	-7.36M	-6.2M	375K	-1.7M	-8.81M	-5.41M	7.82M	19.87M
Interest Income	3.33M	3.75M	4.65M	9.24M	13.98M	6.96M	2.41M	7.63M	30.85M	42.45M
Interest Expense	13.25M	14.89M	12.01M	15.44M	13.6M	8.66M	11.22M	13.04M	23.03M	22.58M
Other Income/Expense	296K	-5.72M	4.63M	-27.84M	-21.58M	15.89M	-10.02M	-25.04M	7.4M	23.11M
Pretax Income+	-224M	-214.39M	-143.27M	-126.97M	-197.06M	-96.54M	87.73M	-31.13M	421.52M	443.75M
Pretax Margin %	-0.36%	-0.29%	-0.16%	-0.12%	-0.17%	-0.09%	0.07%	-0.03%	0.25%	0.28%
Income Tax+	3.16M	-5.94M	14.67M	12.34M	-436K	14.32M	11.33M	2.02M	-97.64M	71.61M
Effective Tax Rate %	1.01%	0.97%	1.1%	1.1%	1%	1.15%	-0.55%	5.08%	0.84%	0.83%
Net Income+	-227.16M	-208.44M	-157.94M	-139.31M	-196.62M	-110.86M	-48.17M	-158.27M	355.76M	367.07M
Net Margin %	-0.36%	-0.28%	-0.17%	-0.13%	-0.17%	-0.11%	-0.04%	-0.14%	0.21%	0.24%
Net Income Growth %	-6.56%	0.08%	0.24%	0.12%	-0.41%	0.44%	0.57%	-2.29%	3.25%	0.03%
Net Income (Continuing)	-227.16M	-208.44M	-157.94M	-139.31M	-196.62M	-110.86M	76.4M	-33.15M	519.16M	372.14M
Discontinued Operations	0	0	0	0	0	0	-124.57M	-125.11M	-163.4M	-5.07M
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1.52	-1.38	-1.03	-0.90	-1.25	-0.70	-0.30	-0.97	2.10	2.17
EPS Growth %	-6.24%	0.09%	0.25%	0.13%	-0.39%	0.44%	0.57%	-2.23%	3.16%	0.03%
EPS (Basic)	-1.52	-1.38	-1.03	-0.90	-1.25	-0.70	-0.30	-0.97	2.14	2.22
Diluted Shares Outstanding	149.21M	151.48M	153.41M	155.11M	157.05M	158.8M	160.94M	163.74M	169.73M	169.2M
Basic Shares Outstanding	149.21M	151.48M	153.41M	155.11M	157.05M	158.8M	160.94M	163.74M	166.22M	165.39M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	1.02B	912.61M	966.06M	983.25M	961.97M	1.11B	1.06B	1.13B	1.49B	1.42B
Cash & Short-Term Investments	798.85M	619.16M	590.72M	539.29M	534.98M	635.03M	536.31M	608.47M	773.49M	751.67M
Cash Only	181.11M	186.38M	191.3M	266.76M	203.77M	272.96M	337.54M	292.47M	457.47M	291.15M
Short-Term Investments	353.67M	310.86M	242.21M	272.53M	331.21M	362.07M	198.77M	315.99M	316.02M	460.52M
Accounts Receivable	155.49M	191.1M	233.59M	300.45M	265.47M	289.54M	326.56M	296.9M	333.18M	389.52M
Days Sales Outstanding	90.32	93.54	94.38	100.22	82.75	101.74	101.55	97.47	73.11	91.28
Inventory	38.41M	63M	93.28M	90.2M	101.8M	125.74M	150.34M	181.42M	186.41M	182.89M
Days Inventory Outstanding	100.87	174.04	220.01	186.61	205.99	257.38	278.08	303.66	268.89	272.1
Other Current Assets	0	0	0	0	0	0	0	43.53M	192.43M	91.28M
Total Non-Current Assets+	836.71M	813.81M	831.17M	841.75M	843.43M	838.76M	962.32M	833.67M	650.72M	640.21M
Property, Plant & Equipment	254.82M	264.79M	284.74M	309.99M	374.55M	481.72M	456.68M	320.46M	318.4M	311.81M
Fixed Asset Turnover	2.47x	2.82x	3.17x	3.53x	3.13x	2.16x	2.57x	3.47x	5.22x	5.00x
Goodwill	92.87M	92.87M	92.87M	92.87M	92.87M	92.87M	92.87M	83.03M	83.03M	83.03M
Intangible Assets	379.19M	318.23M	256.17M	191M	150.64M	111.19M	74.04M	37.68M	1.99M	890K
Long-Term Investments	264.07M	121.93M	157.21M	80.74M	79.39M	24.78M	229.43M	131.61M	39.89M	73.15M
Other Non-Current Assets	-195.09M	-31.77M	-58.38M	81.34M	49.42M	41.97M	27.45M	146.32M	11.52M	16.5M
Total Assets+	1.86B	1.73B	1.8B	1.83B	1.81B	1.95B	2.02B	1.96B	2.14B	2.06B
Asset Turnover	0.34x	0.43x	0.50x	0.60x	0.65x	0.53x	0.58x	0.57x	0.78x	0.76x
Asset Growth %	-0.03%	-0.07%	0.04%	0.02%	-0.01%	0.08%	0.04%	-0.03%	0.09%	-0.04%
Total Current Liabilities+	236.21M	211.99M	291.12M	339.77M	391.11M	438.26M	471.29M	497.74M	520.22M	465.2M
Accounts Payable	37.4M	46.27M	55.53M	39.77M	54.26M	46.03M	55.72M	32.84M	65.65M	45.63M
Days Payables Outstanding	98.22	127.84	130.97	82.28	109.79	94.23	103.07	54.97	94.7	67.89
Short-Term Debt	65.74M	3M	3M	2.84M	2.84M	2.84M	3M	3M	3M	0
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	90.96M	114.26M	176.07M	226.38M	72.07M	71.18M	77.26M	84.93M	359.99M	70.96M
Current Ratio	4.31x	4.30x	3.32x	2.89x	2.46x	2.53x	2.25x	2.27x	2.86x	3.04x
Quick Ratio	4.15x	4.01x	3.00x	2.63x	2.20x	2.25x	1.93x	1.91x	2.50x	2.65x
Cash Conversion Cycle	92.97	139.74	183.42	204.55	178.95	264.89	276.56	346.15	247.3	295.48
Total Non-Current Liabilities+	305.26M	304.95M	303.3M	313.95M	328.85M	444.49M	440.61M	422.48M	413.32M	125.39M
Long-Term Debt	284.21M	280.67M	278.44M	276.46M	274.3M	272.12M	292.8M	290.27M	287.73M	0
Capital Lease Obligations	0	0	0	0	5.34M	119.46M	104.16M	76.29M	75.71M	69.37M
Deferred Tax Liabilities	470K	0	0	0	0	0	0	0	-4.78M	0
Other Non-Current Liabilities	12.61M	17.16M	19.2M	27.96M	27.14M	36.51M	32.16M	55.93M	49.88M	56.02M
Total Liabilities	541.47M	516.94M	594.42M	653.72M	719.96M	882.75M	911.9M	920.23M	933.54M	590.59M
Total Debt+	349.94M	283.67M	281.44M	279.31M	290.95M	410.16M	416.21M	379.44M	372.19M	75.54M
Net Debt	168.84M	97.29M	90.14M	12.55M	87.17M	137.2M	78.66M	86.96M	-85.28M	-215.61M
Debt / Equity	0.27x	0.23x	0.23x	0.24x	0.27x	0.38x	0.37x	0.36x	0.31x	0.05x
Debt / EBITDA	-	-	-	61.63x	-	-	2.36x	5.29x	0.76x	0.17x
Net Debt / EBITDA	-	-	-	2.77x	-	-	0.45x	1.21x	-0.17x	-0.48x
Interest Coverage	-16.93x	-14.01x	-12.32x	-6.42x	-12.90x	-12.98x	8.71x	-0.47x	17.98x	18.63x
Total Equity+	1.31B	1.21B	1.2B	1.17B	1.09B	1.07B	1.11B	1.04B	1.2B	1.46B
Equity Growth %	-0.06%	-0.08%	-0.01%	-0.03%	-0.07%	-0.02%	0.04%	-0.06%	0.15%	0.22%
Book Value per Share	8.81	7.98	7.84	7.55	6.91	6.72	6.91	6.37	7.09	8.66
Total Shareholders' Equity	1.31B	1.21B	1.2B	1.17B	1.09B	1.07B	1.11B	1.04B	1.2B	1.46B
Common Stock	1.52M	1.54M	1.56M	1.58M	1.6M	1.62M	1.66M	1.69M	1.73M	1.77M
Retained Earnings	-739.5M	-947.94M	-1.04B	-1.19B	-1.38B	-1.49B	-1.54B	-1.7B	-1.34B	-976.46M
Treasury Stock	-58.66M	-72.64M	-89.35M	-108.97M	-118.39M	-126.09M	-142.66M	-160.86M	-189.34M	-419.25M
Accumulated OCI	-3.79M	-3.27M	-3.79M	-3.28M	-1.82M	-1.35M	-3.72M	-10.89M	-3.11M	-1.97M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-40.36M	-63.8M	19.19M	99.28M	72.08M	82.84M	101.72M	21.04M	401.35M	439.12M
Operating CF Margin %	-0.06%	-0.09%	0.02%	0.09%	0.06%	0.08%	0.09%	0.02%	0.24%	0.28%
Operating CF Growth %	-4.62%	-0.58%	1.3%	4.17%	-0.27%	0.15%	0.23%	-0.79%	18.07%	0.09%
Net Income	-227.16M	-208.44M	-157.94M	-139.31M	-196.62M	-110.86M	-48.17M	-158.27M	355.76M	367.07M
Depreciation & Amortization	85.6M	94.26M	98.52M	103.66M	80.41M	81.85M	78.65M	77.86M	74.93M	28.53M
Stock-Based Compensation	97.34M	94.4M	83.92M	105.36M	0	90.16M	87.62M	94.25M	100.91M	96.64M
Deferred Taxes	-37.58M	-9.69M	7.23M	10.62M	-319K	9.98M	5.08M	-32.8M	-99.9M	40.52M
Other Non-Cash Items	-40.53M	-7.12M	-7.66M	26.37M	123.2M	-1.43M	4.08M	27.28M	6.33M	4.51M
Working Capital Changes	81.98M	-27.2M	-4.88M	-7.42M	65.41M	13.13M	-25.55M	12.71M	-36.66M	-98.15M
Change in Receivables	-16.45M	-35.62M	-42.49M	-58.63M	29.98M	-18.05M	-38.01M	25.25M	-44.51M	-56.34M
Change in Inventory	19.62M	-26.38M	-30.19M	-2.67M	-13.08M	-22.93M	-24.77M	-31.02M	-2.71M	3.09M
Change in Payables	76.16M	45.87M	72.66M	46.74M	34.85M	59.04M	43.31M	15.53M	23.01M	-57.97M
Cash from Investing+	-43.49M	127.24M	-18.36M	-22.2M	-141.83M	-11.48M	-66.2M	-64.54M	53.36M	-111.31M
Capital Expenditures	-52.88M	-43.66M	-51.3M	-69.43M	-90.94M	-42.22M	-29.02M	-38.26M	-48.05M	-33.48M
CapEx % of Revenue	0.08%	0.06%	0.06%	0.06%	0.08%	0.04%	0.02%	0.03%	0.03%	0.02%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	50.5M	194K	162K	507K	10M	4.53M	8.94M	1.27M	354K	461K
Cash from Financing+	40.89M	-58.17M	4.08M	-1.62M	6.76M	-2.17M	29.07M	-1.57M	-289.71M	-494.14M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	47.64M	7.64M	4.08M	-877K	0	0	0	0	-275M	-2.06M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-93.24M	-107.46M	-32.11M	29.85M	-18.86M	40.62M	72.69M	-17.21M	353.31M	405.64M
FCF Margin %	-0.15%	-0.14%	-0.04%	0.03%	-0.02%	0.04%	0.06%	-0.02%	0.21%	0.26%
FCF Growth %	-3.14%	-0.15%	0.7%	1.93%	-1.63%	3.15%	0.79%	-1.24%	21.53%	0.15%
FCF per Share	-0.62	-0.71	-0.21	0.19	-0.12	0.26	0.45	-0.11	2.08	2.40
FCF Conversion (FCF/Net Income)	0.18x	0.31x	-0.12x	-0.71x	-0.37x	-0.75x	-2.11x	-0.13x	1.13x	1.20x
Interest Paid	12.32M	12.46M	11.14M	12.53M	0	8.29M	6.9M	13.56M	22.75M	23.01M
Taxes Paid	705K	5.53M	2.99M	754K	0	620K	1.89M	20.75M	44.24M	2.59M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-16.76%	-16.52%	-13.1%	-11.74%	-17.43%	-10.3%	-4.42%	-14.68%	31.67%	27.52%
Return on Invested Capital (ROIC)	-11.16%	-11.22%	-8.53%	-6%	-11.17%	-7.1%	6.12%	-0.39%	27.63%	26.66%
Gross Margin	77.88%	82.28%	82.87%	83.88%	84.59%	82.83%	83.19%	80.39%	84.79%	84.25%
Net Margin	-36.15%	-27.95%	-17.48%	-12.73%	-16.79%	-10.67%	-4.1%	-14.24%	21.39%	23.57%
Debt / Equity	0.27x	0.23x	0.23x	0.24x	0.27x	0.38x	0.37x	0.36x	0.31x	0.05x
Interest Coverage	-16.93x	-14.01x	-12.32x	-6.42x	-12.90x	-12.98x	8.71x	-0.47x	17.98x	18.63x
FCF Conversion	0.18x	0.31x	-0.12x	-0.71x	-0.37x	-0.75x	-2.11x	-0.13x	1.13x	1.20x
Revenue Growth	1.54%	18.68%	21.15%	21.13%	7.01%	-11.29%	13%	-5.28%	49.61%	-6.36%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Product	-	-	-	-	524.5M	-	627.42M	777.55M	920M	1.08B
Product Growth	-	-	-	-	-	-	-	23.93%	18.32%	17.78%
Vivitrol	-	-	-	302.61M	335.37M	-	343.85M	379.48M	400.42M	457.31M
Vivitrol Growth	-	-	-	-	10.82%	-	-	10.36%	5.52%	14.21%
Aristada And Aristada Initio	-	-	-	-	-	-	275.36M	302.05M	327.69M	346.19M
Aristada And Aristada Initio Growth	-	-	-	-	-	-	-	9.70%	8.49%	5.64%
L Y B A L V I	-	-	-	-	-	-	8.21M	96.02M	191.89M	280.03M
L Y B A L V I Growth	-	-	-	-	-	-	-	1068.86%	99.84%	45.93%
Manufactured Product And Royalty	-	-	-	-	-	22.5M	-	-	-	-
Manufactured Product And Royalty Growth	-	-	-	-	-	-	-	-	-	-
Research And Development	-	-	-	-	-	1.95M	-	-	-	-
Research And Development Growth	-	-	-	-	-	-	-	-	-	-
License	-	-	-	-	-	1.05M	-	-	-	-
License Growth	-	-	-	-	-	-	-	-	-	-
Aristada Or Aristada Initio	-	-	-	-	189.13M	-	-	-	-	-
Aristada Or Aristada Initio Growth	-	-	-	-	-	-	-	-	-	-
Aristada	-	-	-	147.72M	-	-	-	-	-	-
Aristada Growth	-	-	-	-	-	-	-	-	-	-
B Y D U R E O N	-	-	45.7M	-	-	-	-	-	-	-
B Y D U R E O N Growth	-	-	-	-	-	-	-	-	-	-
R I S P E R D A L C O N S T A	24.2M	22.3M	20.1M	-	-	-	-	-	-	-
R I S P E R D A L C O N S T A Growth	-	-7.85%	-9.87%	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
UNITED STATES	-	-	-	884.6M	966.93M	839M	984.24M	931.99M	1.49B	1.41B
UNITED STATES Growth	-	-	-	-	9.31%	-13.23%	17.31%	-5.31%	60.08%	-5.48%
Foreign Country Excluding Specified Country	175.79M	183.97M	193.58M	204.76M	200.82M	196.53M	187.34M	177.97M	170.29M	146.18M
Foreign Country Excluding Specified Country Growth	-	4.65%	5.22%	5.78%	-1.92%	-2.14%	-4.67%	-5.00%	-4.32%	-14.16%
IRELAND	-	-	-	4.92M	3.19M	3.23M	2.17M	1.83M	1.18M	1.29M
IRELAND Growth	-	-	-	-	-34.99%	1.19%	-32.73%	-15.91%	-35.54%	9.75%
U	448.64M	557.31M	700.09M	-	-	-	-	-	-	-
U Growth	-	24.22%	25.62%	-	-	-	-	-	-	-
I	3.9M	4.41M	9.71M	-	-	-	-	-	-	-
I Growth	-	12.94%	120.24%	-	-	-	-	-	-	-

Frequently Asked Questions

Valuation & Price

Alkermes plc (ALKS) has a price-to-earnings (P/E) ratio of 14.1x. This may indicate the stock is undervalued or faces growth challenges.

Growth & Financials

Alkermes plc (ALKS) reported $1.52B in revenue for fiscal year 2024. This represents a 290% increase from $390.0M in 2011.

Alkermes plc (ALKS) saw revenue decline by 6.4% over the past year.

Yes, Alkermes plc (ALKS) is profitable, generating $338.8M in net income for fiscal year 2024 (23.6% net margin).

Dividend & Returns

Alkermes plc (ALKS) has a return on equity (ROE) of 27.5%. This is excellent, indicating efficient use of shareholder capital.

Alkermes plc (ALKS) generated $490.9M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.